Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Business Wire•09/11/2026•16:01 ET
0
Key Highlights
- ➤$1.05 billion cash, equivalents, and investments supports operations into 2030
- ➤DT120 ODT Phase 3 Voyage met primary and key secondary GAD endpoints
- ➤DT120 ODT Phase 3 Panorama met primary and key secondary GAD endpoints
- ➤FDA granted DT120 ODT Breakthrough Therapy designation for MDD
- ➤$51.0 million quarterly net loss versus $67.3 million year over year
Expert Statements
Rob Barrow, Chief Executive Officer of Definium Therapeutics
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer of Definium Therapeutics
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD)
Get started
Create a free account to read the full story.